Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. [electronic resource]
Producer: 20150127Description: 386 p. digitalISSN:- 1471-2407
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Docetaxel
- Double-Blind Method
- Doxorubicin -- administration & dosage
- Female
- Filgrastim
- Follow-Up Studies
- Granulocyte Colony-Stimulating Factor -- therapeutic use
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Neutropenia -- chemically induced
- Polyethylene Glycols
- Prognosis
- Recombinant Proteins -- therapeutic use
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.